GlobalData on MSN

Edwards solidifies TAVR dominance in long-term trial readout

The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.
MassDevice

Medtronic launches new guidewire to support TAVR procedures

Medtronic today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.
Medpage Today on MSN

First 7-Year Report of Low-Risk TAVR Reassures, With Finish Line Now in Sight

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...
MassDevice

Edwards shares superior long-term outcomes from TAVR studies

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.
The New England Journal of Medicine

Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...
TCTMD

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

Our initial experience with the DurAVR ® THV System has been very positive, and we look forward to providing definitive comparative evidence which could transform patient care.” “With the first ...